GlassScriptPhysician profile
J Benjamin Matheny
NPI 1255325098
$5,723.88
in general payments reported to CMS, 2019-2025
36 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.54 · 2022: $1,312 · 2023: $1,248 · 2024: $1,402 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,327.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $890.23 | 2022-2025 | Airsupra, Farxiga |
| Abbvie INC. | $730.00 | 2021-2025 | |
| Novo Nordisk INC | $481.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $469.62 | 2022-2025 | |
| Lilly USA, LLC | $410.30 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $384.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $334.58 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $281.83 | 2022-2025 | Evenity, Prolia, Otezla |
| Axsome Therapeutics, INC. | $216.29 | 2024-2025 | Auvelity |
| Abbott Laboratories | $211.54 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $141.84 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $141.34 | 2022 | |
| Astellas Pharma US INC | $129.49 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.01 | 2025 | Caplyta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $82.42 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.18 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.71 | 2022-2023 | Jardiance |
| Lundbeck LLC | $65.15 | 2024-2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $57.03 | 2022-2023 | Linzess |
| Edwards Lifesciences Corporation | $47.93 | 2025 | Sapien 3 Ultra Resilia |
| Otsuka America Pharmaceutical, INC. | $37.65 | 2023-2025 | Rexulti |
| Antares Pharma, INC. | $28.47 | 2024-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $27.82 | 2022 | |
| Daiichi Sankyo INC. | $26.36 | 2024 | Injectafer |
| Sumitomo Pharma America, INC. | $23.33 | 2025 | Gemtesa |
| Medtronic, INC. | $21.82 | 2024 | Interstim |
| Corium, LLC | $21.27 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $18.64 | 2025 | Gardasil 9, Enflonsia, Vaxneuvance |
| Amneal Pharmaceuticals LLC | $16.65 | 2023 | Unithroid |
| Shield Therapeutics INC | $16.59 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.62 | 2023 | Spravato |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Exact Sciences Corporation | $14.77 | 2025 | The Cologuard Plus Collection Kit |
| Almatica Pharma LLC | $14.55 | 2024 | Loreev Xr, Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Benjamin Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.